Chris Nave is a founding partner of Brandon Capital Partners and Principal Executive of the Medical Research Commercialization Fund. Chris previously was Director of Commercialization at the Baker IDI Heart and Diabetes Institute, Melbourne Australia, where he was responsible for the commercialization of technologies developed at the Baker and the Alfred Hospital.
Prior to this, Chris was the Manager of the Biotechnology Team at Melbourne Ventures, the commercialization company of the University of Melbourne. Concurrently during this period, he was an investment manager for, and on the investment committee of, UniSeed Pty Limited. Chris has international business development experience with Leiras Pharmaceuticals in Finland, a wholly owned subsidiary of Schering AG.
Chris is currently a Director of Spinifex Pharmaceuticals, Fibrotech Therapeutics, and BACE Therapeutics. Chris has a first-class Honors degree in Science and PhD in Endocrinology and Physiology from the University of Melbourne. He recently completed the Private Equity and Venture Executive Program at Harvard Business School (Boston USA) and is completing a Graduate Diploma in Intellectual Property Law at the University of Melbourne. Chris a graduate of the Australian Institute of Company Directors. He is a member of Ausbiotech and the BioMelbourne Network.